Radiofrequency applications in congenital heart disease

• Published in: Expert review of cardiovascular therapy Vol. 2; no. 1; pp. 117 - 126
• Main Authors: Veldtman, Gruschen R, Hartley, Amanda, Visram, Naheed, Benson, Lee N
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.01.2004; Taylor & Francis; Expert Reviews Ltd
• Subjects: Adolescent; Animals; Cardiac Catheterization - instrumentation; Care and treatment; Catheter Ablation - instrumentation; Child; Child, Preschool; Congenital heart disease; Genetic disorders; Health aspects; Heart Defects, Congenital - surgery; Heart diseases; Humans; hypoplastic left heart; Infant; Infant, Newborn; intact interatrial septum; percutaneous left atrial access; pulmonary atresia; Radiofrequency ablation; radiofrequency perforation; Canada
• ISSN: 1477-9072; 1744-8344
• DOI: 10.1586/14779072.2.1.117

The relatively recent application of radiofrequency technologies in the treatment of congenital heart defects has provided a safe and effective alternative to conventional therapies in establishing endovascular patency for a variety of lesions. Radiofrequency, with typically used frequencies of approximately 500 kHz, does not cause pain and is unlikely to induce atrial or ventricular fibrillation. It can be used either to ablate [higher power [35-50W]; longer duration of application [90-120 sec]; lower voltage [30-50V]) or to perforate (lower power [5-10W] shorter duration of application [1-5 sec], higher voltage [150-280V]). In the past, perforating radiofrequency has been applied to establish right ventricular outflow tract patency in pulmonary atresia with intact septum and with ventricular septal defect. More recently radiofrequency has been shown to be effective at recanalizing central and peripheral vasculature and has also been applied in establishing percutaneous left heart access. A new radiofrequency catheter, dedicated to transseptal left atrial cannulation, has been demonstrated to be safe and effective in an animal model and is now ready for clinical trials.